Hyderabad-based pharmaceutical major Natco Pharma posted a 15.6% drop in net profit to Rs 28.23 crore for the first quarter ending June 30 this fiscal, as against a net of Rs 33.46 crore for the corresponding period last fiscal.
Total income, however, saw a marginal 6.5% rise to Rs 223.71 crore during the quarter under review, as against Rs 209.96 crore for the same period last financial year.
Profitability took a hit owing to the poor performance of the bulk chemicals segment, whose revenues during the quarter fell around 35% to Rs 55.80 crore, when compared with Rs 85.27 crore last year. The segment registered around 72% decline in profit to Rs 11.34 crore during the quarter, as against Rs 39.57 crore last year.
However, formulations business stood the ground registering a 57.7% jump in revenues to Rs 141.46 crore, as against Rs 89.66 crore last year, and profit from the segment almost doubled to Rs 57.12 crore, from Rs 30.68 crore in the same period last fiscal.
The company expects strong sales growth in high margin products in the remaining quarters of the current fiscal, it stated in a release today.
Meanwhile, the board of directors recommended sub-division of face value of its equity shares from the earlier Rs 10 each to Rs 2.
Shares of Natco Pharma dropped 2.38% to close at Rs 2,410.65 on the BSE on Wednesday, as against the previous day's closing of Rs 2,469.45.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)